Axsome Therapeutics Inc (AXSM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Axsome Therapeutics Inc (AXSM) has a cash flow conversion efficiency ratio of -0.379x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-20.70 Million) by net assets ($54.59 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See AXSM equity to assets ratio to measure how much of total assets are equity-financed.
Axsome Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Axsome Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check AXSM cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Axsome Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Axsome Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Washington H Soul Pattinson & Company Ltd
AU:SOL
|
-0.041x |
|
Indian Railway Finance Corporation Limited
NSE:IRFC
|
-0.247x |
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SHG:600436
|
0.007x |
|
Julius Baer Gruppe AG
SW:BAER
|
0.767x |
|
Postal Savings Bank of China Co Ltd
F:3YB
|
0.053x |
|
Taiwan Union Technology
TWO:6274
|
-0.087x |
|
Aptiv PLC
NYSE:APTV
|
-0.015x |
|
UPM-Kymmene Oyj
HE:UPM
|
0.017x |
Annual Cash Flow Conversion Efficiency for Axsome Therapeutics Inc (2013–2025)
The table below shows the annual cash flow conversion efficiency of Axsome Therapeutics Inc from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see Axsome Therapeutics Inc market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $88.30 Million | $-93.41 Million | -1.058x | +53.03% |
| 2024-12-31 | $57.02 Million | $-128.41 Million | -2.252x | -196.47% |
| 2023-12-31 | $190.98 Million | $-145.08 Million | -0.760x | +28.57% |
| 2022-12-31 | $109.56 Million | $-116.51 Million | -1.063x | +84.64% |
| 2021-12-31 | $15.63 Million | $-108.23 Million | -6.924x | -904.27% |
| 2020-12-31 | $113.79 Million | $-78.46 Million | -0.689x | -165.71% |
| 2019-12-31 | $178.72 Million | $-46.38 Million | -0.259x | +99.19% |
| 2018-12-31 | $937.92K | $-30.05 Million | -32.043x | -1923.55% |
| 2017-12-31 | $16.72 Million | $-26.47 Million | -1.583x | -60.51% |
| 2016-12-31 | $21.57 Million | $-21.28 Million | -0.987x | -515.94% |
| 2015-12-31 | $46.44 Million | $-7.44 Million | -0.160x | -111.16% |
| 2014-12-31 | $-3.20 Million | $-4.60 Million | 1.435x | +78.43% |
| 2013-12-31 | $-2.03 Million | $-1.63 Million | 0.804x | -- |
About Axsome Therapeutics Inc
Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment… Read more